Fig 1: Effects of IFN-a on human HCC cell lines. (A) Huh7, HLCZ01, SMMC7721, and LH86 cells were treated with 125, 250, 500, 1,000, 2,000 or 4,000 IU/mL IFN-a for (A) 24 h, (B) 48 h, (C) and 72 h, and cell viability was assessed by MTT assay. (D) Expression of the ISG15 and ISG12a proteins was detected by western blotting using ß-actin as a loading control. The data presented are representative of 3 independent experiments.
Fig 2: Protein expression patterns upon vemurafenib treatment in melanoma. (A) Quantitative analysis of positive and negative cells from whole-section scanned images. N = 3 tumors in each groups. (B) Representative immunohistochemical staining pictures of P-gp, GPR39, F4/80, and GNRHR proteins. Black arrows indicate F4/80-positive macrophages. Scale bars: 50 µm. (C) Western blot images showing protein level changes of CD27 and IFI27. Three control and three treated animal samples were measured.
Fig 3: Relative mRNA expression changes of melanoma PDTX tissue upon vemurafenib treatment. All panels show relative expressions, normalized to control RPLP0. All measurements were analyzed in a common study to ensure the common threshold values for cT determination. Genes systematically upregulated (GPR39, CD27, SLC15A3, PDGFA, ABCB1) or downregulated (IFI27) after vemurafenib treatment. *: p < 0.05; **: p < 0.01.
Supplier Page from Abcam for Anti-IFI27 antibody